All posts by Genetic Signatures
For a second year, Genetic Signatures Ltd are proudly exhibiting at the 25th International Molecular Medicine TRI-Conference (MMTC) in San Francisco, CA on 12th-14thFebruary 2018.
Our US operations team will be exhibiting our growing number of EasyScreenTM viral and infectious disease reagents. Formulated on our proprietary 3base™ technology, the EasyScreenTM reagents fosters more efficient detection of infectious microorganisms, within a streamlined workflow solution. The EasyScreenTM reagents includes targets for diagnosing bacterial, viral and protozoan causes of gastroenteritis; respiratory infections, sexually transmitted infections, and antibiotic resistance.
Visit Genetic Signatures at Booth 221 MMTC 2018 for more information
Don’t forget to follow us on Twitter @GeneticSig for updates throughout the conference.
About MMTC 2018: MMTC also known as Tri-Con, is an annual precision medicine event attracting over 3,700 drug discovery and development professionals worldwide. Spanning five days, the 2018 meeting includes over 500 fellow industry and academic colleagues discussing themes of cancer research, big data, molecular diagnostics, precision medicine, rare diseases, data science, human microbiome, point-of-care diagnostics, infectious diseases, and so much more.
Genetic Signatures are pleased to inform our customers and distributors that we have recently relocated our Sydney Office.
Our relocation enables advancement of our growth expectations for the future and further support our customers through our commitment of high quality products and services.
Our contact number will remain unchanged.
Our new address:
7 Eliza Street, Newtown NSW 2042 Australia.
Genetic Signatures Limited (ASX: GSS) held its 2017 Annual General Meeting on Tuesday 28 November 2017 at 11.00am (AEST).
Genetic Signatures are exhibiting at the Association for Molecular Pathology (AMP) Annual meeting 2017 in Salt Lake City, Utah 16-18 November.
The AMP Annual Meeting is:
- The premier educational event for molecular pathology professionals from around the world.
- The only educational event developed and presented by internationally renowned molecular diagnostic professionals.
- The dedicated forum for first-time presentation of rigorously peer-reviewed abstracts, destined for publication in The Journal of Molecular Diagnostics.
- The source for practical applications of clinically proven molecular diagnostics – ultimately improving patient care.
You are invited to visit Genetic Signatures at Booth no. 1005 at AMP 2017 for more information.
Click here to visit the AMP 2017
The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP’s 2,300+ members practice in the various disciplines of molecular diagnostics, including bioinformatics, infectious diseases, inherited conditions, and oncology. Our members include pathologists, doctoral scientist laboratory directors, basic and translational scientists, technologists, and trainees from academic and community medical centers, government, and industry. Through the efforts of its Board of Directors, Committees, Working Groups, and Members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing.
Genetic Signatures EasyScreen™ Pathogen Detection Kits will be featured in an oral presentation at the upcoming National Reference Laboratory (NRL) Workshop on Molecular Diagnostics on the 16-17th October 2017 Hobart, Australia.
The presentation entitled “A 3baseTM Real-Time Multiplex-PCR for the detection of Extended- Spectrum β -Lactamases (ESBL) and Carbapenemase- Producing Organisms (CPO) will be given by our talented Product Development Scientist Mr. Dilshan Abeysekera.
The NRL Molecular Workshop is a forum for scientists, regulators, test kit manufacturers and clinicians to unite and discuss current issues and new technologies occurring in the world of molecular pathology for infectious diseases. The aim of this workshop is to focus specifically on molecular techniques involved in detecting infectious pathogens.
Visit the conference website for more information: NRL Molecular Diagnostic Workshop
About ESBL and CPO: ESBLs are enzymes that mediate resistance to extended-spectrum (third generation) cephalosporins and monobactams but do not affect cephamycins or carbapenems. The presence of an ESBL-producing organism in a clinical infection can result in treatment failure if one of the above classes of drugs is used. ESBLs can be difficult to detect because they have different levels of activity against various cephalosporins. Thus, the choice of which antimicrobial agents to test is critical. 1
CPO or CRE, which stands for carbapenem-resistant Enterobacteriaceae or organisms, are a family of germs that are difficult to treat because they have high levels of resistance to antibiotics. Klebsiella species and Escherichia coli (E. coli) are examples of Enterobacteriaceae, a normal part of the human gut bacteria, that can become carbapenem-resistant. Types of CRE are sometimes known as KPC (Klebsiella pneumoniae carbapenemase) and NDM (New Delhi Metallo-beta-lactamase). KPC and NDM are enzymes that break down carbapenems and make them ineffective. Both of these enzymes, as well as the enzyme VIM (Verona Integron-Mediated Metallo-β-lactamase) have also been reported in Pseudomonas.
Healthy people usually do not get CRE infections – they usually happen to patients in hospitals, nursing homes, and other healthcare settings. Patients whose care requires devices like ventilators (breathing machines), urinary (bladder) catheters, or intravenous (vein) catheters, and patients who are taking long courses of certain antibiotics are most at risk for CRE infections.
Some CRE bacteria have become resistant to most available antibiotics. Infections with these germs are very difficult to treat, and can be deadly—one report cites they can contribute to death in up to 50% of patients who become infected.2
About the EasyScreen™ Antibiotic Resistance Detection Kit: The EasyScreen™ Antibiotic Resistance Detection Kit detects the most common resistant markers. ESBL and CPO targets that are detected are β –Lactamases TEM, SHV, CTX-M, CMY, DHA,OXA-48 like , OXA- 23 like, OXA-51 like, GES, MCR-1,IMI,SME, , New Delhi Metallo- β –Lactamases (NDM), Klebsiella pneumoniae carbapenemase (KPC), Metallo- β –Lactamases VIM, Metallo- β –Lactamases IMP.